XW004

XW004 is an oral tablet formulation of ecnoglutide, a novel long-acting, acylated human glucagon-like peptide 1 (GLP-1) analogue. It is designed for the treatment of type 2 diabetes mellitus and obesity. Ecnoglutide acts as a cAMP signaling biased GLP-1 receptor agonist, optimized for improved biological activity and stability. The oral formulation uses an absorption enhancer to prevent degradation in the digestive tract, enabling daily or potentially once-weekly dosing. In phase 1 clinical trials, XW004 demonstrated significant reductions in body weight and favorable safety/tolerability consistent with other GLP-1 agonists[1][3][6][8].

Other names

oral ecnoglutideecnoglutide tablet